As the pace of the two sessions of the National People's Congress is getting closer and closer, the deputies of the National People's Congress and the members of the National Committee of the Chinese People's Political Consultative Conference in Hangzhou are also getting busier. Before going to Beijing, the representatives and members went deep into the grassroots to conduct research, listen to social conditions and public opinions, revise and improve suggestions and proposals, and make final preparations for the meeting.
The main purpose of this meeting this afternoon is to understand the needs of supporting the construction of China's medical port, and to listen to the opinions and demands of pharmaceutical companies, so as to further revise and improve the proposals. On the afternoon of February 28, Fang Xiaohong, deputy director of the Hangzhou Institute of Medical Sciences of the Chinese Academy of Sciences, sat with the people of the Hangzhou Medical Port Management Office and held a brief research meeting.
As a new representative, learning and research are the two key words that Fang Xiaohong has performed in the past year. She actively participates in learning and training, performance research, and improves her ability to perform her duties through continuous learning and "charging". After more than a year, Fang Xiaohong has a deeper understanding of the duties and missions of people's congress deputies, "People's congress deputies must listen to the voices of the masses, reflect the demands of the masses, and be a good bridge between the country and the masses." ”
Whether it is attending the meeting or conducting research and investigation, Fang Xiaohong is very serious, and she will record the suggestions related to the biomedical industry and enterprises one by one. "In the process of participating in the conference and research, I heard the voices of many biomedical companies, such as the lack of leading talents. Fang Xiaohong said that the Hangzhou Institute of Medical Sciences will follow the mission of the "national team", give full play to the advantages of the Chinese Academy of Sciences systematization, actively introduce and cultivate first-class biomedical talents, and provide talent support for the high-quality development of the biomedical industry in Zhejiang Province and Hangzhou.
To seize the commanding heights of science and technology, talent is the top priority. As a scientific research worker, strengthening the cultivation of high-level scientific and technological talents is the focus of Fang Xiaohong this year. She suggested that the expansion and quality of postgraduate education should be promoted, especially the high-quality development of doctoral education. At the same time, efforts should be made to promote the reform of personnel management of scientific research institutes, improve the stability of the scientific research team, comprehensively stimulate the innovation vitality of young scientific research personnel, and consolidate the talent foundation of scientific and technological self-reliance and self-reliance.
Ding Lieming, a member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) and chairman of Betta Pharmaceutical Co., Ltd., is an "old acquaintance" of the National People's Congress and the National People's Congress - this year is his 12th year to participate in the National People's Congress and the National People's Political Consultative Conference, but the voice of Hangzhou brought by him to Beijing every year is full of "new ideas". As a committee member from the biomedical field, Ding Lieming has always been concerned about pharmaceutical innovation.
At the two sessions of the National People's Congress last year, he focused on the proposal of "Strengthening the R&D and Technical Review of Individualized Customized Drugs in the Era of Precision Medicine", and after making a group speech at the CPPCC meeting, he received the ** from the State Food and Drug Administration that night to learn the details of the proposal.
In April 2023, the State Food and Drug Administration issued the "Technical Guidelines for Clinical Trials of Tumor Active Immunity** Products" and approved more than 100 cell and gene ** products to carry out clinical trials, including personalized tumor active immunity** products with a variety of technical routes.
In the past 11 years, I have submitted more than 60 proposals from representatives and committee members in the fields of pharmaceutical innovation and economic development through the National People's Congress and the National People's Congress and the National People's Congress (NPC), and many of the suggestions have been absorbed and adopted, thereby promoting the development of the entire industry, which I think is very meaningful. In the past year, Ding Lieming has visited and investigated dozens of enterprises in the field of life and health, communicated with industry experts and scholars, and collected a lot of people's demands and views on the approval process of innovative medical devices, the development of cutting-edge biomedical technologies, and the introduction of high-level talents through channels such as the Federation of Overseas Chinese, the Peasants and Workers Party, the China Pharmaceutical Promotion Association, and the Zhejiang Pharmaceutical Industry Association.
In recent years, through the introduction of talents and policy guidance, Hangzhou has gathered a large number of pharmaceutical innovation enterprises, and the development momentum is very good, but it is also facing some difficulties, such as the difficulty of corporate financing leading to the death of some R&D projects in the middle of the process. Ding Lieming said that it is his responsibility as a member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) to reflect the current problems of the development of the industry in a timely manner, optimize the ecosystem of innovation and entrepreneurship, and let more pharmaceutical innovation blossom and bear fruit on the land of China.